| __timestamp | Madrigal Pharmaceuticals, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 15746000 | 10811000 |
| Thursday, January 1, 2015 | 13392000 | 33001000 |
| Friday, January 1, 2016 | 9290000 | 64936000 |
| Sunday, January 1, 2017 | 7672000 | 99909000 |
| Monday, January 1, 2018 | 15293000 | 127724000 |
| Tuesday, January 1, 2019 | 22648000 | 161524000 |
| Wednesday, January 1, 2020 | 21864000 | 182933000 |
| Friday, January 1, 2021 | 37318000 | 219982000 |
| Saturday, January 1, 2022 | 48130000 | 278139000 |
| Sunday, January 1, 2023 | 108146000 | 309799000 |
Unleashing insights
In the competitive landscape of biotechnology, effective cost management is crucial. Madrigal Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Madrigal's Selling, General, and Administrative (SG&A) expenses surged by over 580%, peaking in 2023. Meanwhile, Ultragenyx's expenses grew by approximately 280% during the same period, reflecting its aggressive expansion strategy.
Madrigal's expenses remained relatively stable until 2020, after which they more than doubled, indicating a strategic shift or increased operational activities. Ultragenyx, on the other hand, consistently increased its SG&A spending, with a notable jump in 2015 and a steady rise thereafter. This trend suggests a focus on scaling operations and market presence.
Understanding these trends provides valuable insights into how these companies manage their growth and operational strategies.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Ultragenyx Pharmaceutical Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: BeiGene, Ltd. vs Ultragenyx Pharmaceutical Inc. Trends and Insights
United Therapeutics Corporation vs Ultragenyx Pharmaceutical Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Insmed Incorporated vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Madrigal Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Madrigal Pharmaceuticals, Inc. and CRISPR Therapeutics AG
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Veracyte, Inc. Trends and Insights
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs HUTCHMED (China) Limited Trends and Insights
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Merus N.V.
Ultragenyx Pharmaceutical Inc. vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and Viridian Therapeutics, Inc.